The world's first CDK2/4/6 inhibitor, developed by Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical, was officially approved for market launch on Thursday. CDK2/4/6 ...

Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the ...

The final, formatted version of the article will be published soon. Objective: DPP-4 inhibitors are now established agents for glycaemic control in diabetes. Herein, this study systematically ...

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors.

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Compared with the use of SGLT2 inhibitors, the use of GLP-1 receptor agonists and DPP-4 inhibitors was associated with a similar risk for acute pancreatitis (hazard ratio [HR], 1.01; 95% CI, 0.90-1.13 ...

Among patients with diabetes who require in-center hemodialysis, the use of GLP-1 receptor agonists is associated with a lower risk of developing Alzheimer disease and related dementias compared with ...

HONOLULU (HawaiiNewsNow) - The Honolulu Department of Planning and Permitting announced the launch of CivCheck, a free new artificial intelligence software designed to help prepare permit applications ...